Evelo Biosciences to Present Clinical Data from Phase 1/2 Trial of EDP1503 at the ESMO World Congress on Gastrointestinal Cancer Virtual Meeting

CAMBRIDGE, Mass., July 01, 2020 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting biologics, today announced that clinical data from the Phase 1/2 open-label study of EDP1503, in combination with pembrolizumab, in patients with advanced metastatic microsatellite stable colorectal carcinoma (MSS CRC), triple-negative breast cancer (TNBC), and checkpoint inhibitor relapsed tumors, will be presented at the ESMO World Congress on Gastrointestinal Cancer Virtual Meeting being held July 1 - 4, 2020.

In addition to data in MSS CRC patients, the poster reported preliminary data on 11 TNBC patients (8 on high dose and 3 on low dose EDP1503). An overall response rate (ORR) of 25% (2/8) and a disease control rate of 37.5% (3/8) were observed across all TNBC subjects receiving high dose EDP1503. ORR was 33% (2/6) amongst response-evaluable patients on the high dose, with 2 patients awaiting first response assessment. Historic studies of anti-PD-1 monotherapy in heavily pretreated TNBC patients have yielded an ORR of 5-10%. The study continues enrollment in TNBC, and further data from this cohort will be available in 4Q 2020.

Details of the poster are as follows:

Title: EDP1503 induces antitumor responses via gut-mediated activation of both innate and adaptive immunity
Poster Session Date: July 1-4, 2020
Abstract ID: P-325
Category: Clinical Colon Cancer
Authors: Loise Francisco-Anderson, PhD; Shamira Shariffudin; Humphrey Gardner, MD; Michael Goldberg, PhD; Shubhra Kashyap, MS; Mary Abdou; Chris Davitt, PhD; Shannon Argueta, PhD; Pooja Parameswaran, MS; Peter Sandy, PhD; Holly Ponichtera, PhD; Mark Carlson; Maria Sizova, PhD; Valeria Kravitz; Erin Troy, PhD; Sam Andrewes, MS; Johanna C. Bendell, MD; Judy S. Wang, MD; Susanna V. Ulahannan, MD; Michael Chisamore, PhD; Mark Bodmer, PhD; and Duncan McHale, MD

The poster is available online on the ESMO conference website, as well as on the Evelo website, under the “publications” tab.

About Evelo Biosciences
Evelo Biosciences is a clinical stage biotechnology company developing oral biologics that act on SINTAX™, the small intestinal axis, with systemic therapeutic effects. SINTAX plays a central role in governing the immune, metabolic and neurological systems. The company’s first product candidates are pharmaceutical preparations of single strains of microbes selected for defined pharmacological properties. Evelo’s therapies have the potential to be effective, safe, and affordable medicines to improve the lives of people with inflammatory diseases and cancer.

Evelo currently has four product candidates in development: EDP1815, EDP1867, and EDP2939 for the treatment of inflammatory diseases including psoriasis, atopic dermatitis, and COVID-19, and EDP1503 for the treatment of cancer. Evelo is advancing additional product candidates in other disease areas.

For more information, please visit www.evelobio.com and engage with Evelo on LinkedIn.